PharmacyCodes



Dihydroergotoxin Mesilat en es it fr

Dihydroergotoxin Mesilat Brand names, Dihydroergotoxin Mesilat Analogs

Dihydroergotoxin Mesilat Brand Names Mixture

  • No information avaliable

Dihydroergotoxin Mesilat Chemical_Formula

C33H45N5O5

Dihydroergotoxin Mesilat RX_link

No information avaliable

Dihydroergotoxin Mesilat fda sheet

Dihydroergotoxin Mesilat msds (material safety sheet)

Dihydroergotoxin Mesilat Synthesis Reference

No information avaliable

Dihydroergotoxin Mesilat Molecular Weight

591.741 g/mol

Dihydroergotoxin Mesilat Melting Point

No information avaliable

Dihydroergotoxin Mesilat H2O Solubility

No information avaliable

Dihydroergotoxin Mesilat State

Solid

Dihydroergotoxin Mesilat LogP

2.615

Dihydroergotoxin Mesilat Dosage Forms

Capsule; Liquid; Powder; Powder for solution; Solution; Syrup; Tablet

Dihydroergotoxin Mesilat Indication

For use as an adjunct therapy for patients with dementia

Dihydroergotoxin Mesilat Pharmacology

Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.

Dihydroergotoxin Mesilat Absorption

Rapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.

Dihydroergotoxin Mesilat side effects and Toxicity

Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.

Dihydroergotoxin Mesilat Patient Information

No information avaliable

Dihydroergotoxin Mesilat Organisms Affected

Humans and other mammals